{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:21:40Z","timestamp":1771381300307,"version":"3.50.1"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.aohep.2021.100564","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T08:19:12Z","timestamp":1634890752000},"page":"100564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"S1","title":["The ITA.LI.CA Consortium: How multicentre collaboration helped shape the management of patients with hepatocellular carcinoma on the basis of real-world evidence"],"prefix":"10.1016","volume":"27","author":[{"given":"Franco","family":"Trevisani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo G.","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.aohep.2021.100564_bib0001","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2021-0425","article-title":"Use of real-world evidence for oncology clinical decision making in emerging economies","author":"Petracci","year":"2021","journal-title":"Future Oncol"},{"issue":"3","key":"10.1016\/j.aohep.2021.100564_bib0002","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.28368","article-title":"Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study","volume":"63","author":"Piscaglia","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.aohep.2021.100564_bib0003","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jhep.2011.11.022","article-title":"Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population","volume":"56","author":"Cucchetti","year":"2012","journal-title":"J Hepatol."},{"issue":"2","key":"10.1016\/j.aohep.2021.100564_bib0004","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jhep.2014.03.037","article-title":"Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma","volume":"61","author":"Cucchetti","year":"2014","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.aohep.2021.100564_bib0005","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/hepr.12672","article-title":"Italian Liver Cancer (ITA.LI.CA) group. Length time bias in surveillance for hepatocellular carcinoma and how to avoid it","volume":"46","author":"Cucchetti","year":"2016","journal-title":"Hepatol Res"},{"issue":"7","key":"10.1016\/j.aohep.2021.100564_bib0006","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/apt.13554","article-title":"Years of life that could be saved from prevention of hepatocellular carcinoma","volume":"43","author":"Cucchetti","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.aohep.2021.100564_bib0007","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1053\/j.seminoncol.2014.03.006","article-title":"Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype","volume":"41","author":"Carr","year":"2014","journal-title":"Semin Oncol"},{"issue":"3","key":"10.1016\/j.aohep.2021.100564_bib0008","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1053\/j.seminoncol.2014.04.002","article-title":"Identification of two clinical hepatocellular carcinoma patient phenotypes from results of standard screening parameters","volume":"41","author":"Carr","year":"2014","journal-title":"Semin Oncol"},{"issue":"3","key":"10.1016\/j.aohep.2021.100564_bib0009","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.5301\/jbm.5000064","article-title":"Significance of platelet and AFP levels and liver function parameters for HCC size and survival","volume":"29","author":"Carr","year":"2014","journal-title":"Int J Biol Markers"},{"issue":"4","key":"10.1016\/j.aohep.2021.100564_bib0010","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.5301\/jbm.5000092","article-title":"Low alpha-fetoprotein HCC and the role of GGTP","volume":"29","author":"Carr","year":"2014","journal-title":"Int J Biol Markers"},{"issue":"4","key":"10.1016\/j.aohep.2021.100564_bib0011","doi-asserted-by":"crossref","first-page":"178","DOI":"10.4172\/2329-6771.1000178","article-title":"A liver index and its relationship to indices of HCC aggressiveness","volume":"5","author":"Carr","year":"2016","journal-title":"J Integr Oncol"},{"issue":"4","key":"10.1016\/j.aohep.2021.100564_bib0012","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/1724600818776838","article-title":"Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patients","volume":"33","author":"Carr","year":"2018","journal-title":"Int J Biol Markers"},{"issue":"4","key":"10.1016\/j.aohep.2021.100564_bib0013","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3390\/cancers13040592","article-title":"Identification of clinical phenotypes and related survival in patients with large HCCs","volume":"13","author":"Carr","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.aohep.2021.100564_bib0014","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/1724600821996372","article-title":"Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter","volume":"36","author":"Carr","year":"2021","journal-title":"Int J Biol Markers"},{"issue":"10","key":"10.1016\/j.aohep.2021.100564_bib0015","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1002\/lt.24214","article-title":"Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor","volume":"21","author":"Vitale","year":"2015","journal-title":"Liver Transpl"},{"issue":"7","key":"10.1016\/j.aohep.2021.100564_bib0016","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S1470-2045(11)70144-9","article-title":"Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study","volume":"12","author":"Vitale","year":"2011","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.aohep.2021.100564_bib0017","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jhep.2014.10.037","article-title":"Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study","volume":"62","author":"Vitale","year":"2015","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.aohep.2021.100564_bib0018","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.3390\/cancers13071673","article-title":"Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications","volume":"13","author":"Vitale","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.aohep.2021.100564_bib0019","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s11605-018-3688-y","article-title":"Utility of tumor burden score to stratify prognosis of patients with hepatocellular cancer: Results of 4759 Cases from ITA.LI.CA Study Group","volume":"22","author":"Vitale","year":"2018","journal-title":"J Gastrointest Surg"},{"issue":"4","key":"10.1016\/j.aohep.2021.100564_bib0020","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/hep.30185","article-title":"Restaging patients with hepatocellular carcinoma before additional treatment decisions: A multicenter cohort study","volume":"68","author":"Vitale","year":"2018","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.aohep.2021.100564_bib0021","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/liv.14154","article-title":"The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study","volume":"39","author":"Vitale","year":"2019","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.aohep.2021.100564_bib0022","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/hep.27431","article-title":"Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis","volume":"61","author":"Berzigotti","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2021.100564_bib0023","article-title":"Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis","author":"Sapena","year":"2021","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.aohep.2021.100564_bib0024","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1572-0241.2002.05557.x","article-title":"Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience)","volume":"97","author":"Trevisani","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.aohep.2021.100564_bib0025","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1056\/NEJM199109053251002","article-title":"Hepatocellular carcinoma in Italian patients with cirrhosis","volume":"325","author":"Colombo","year":"1991","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.aohep.2021.100564_bib0026","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2011.05.026","article-title":"The changing scenario of hepatocellular carcinoma over the last two decades in Italy","volume":"56","author":"Santi","year":"2012","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2021.100564_bib0027","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/liv.13204","article-title":"The evolutionary scenario of hepatocellular carcinoma in Italy: an update","volume":"37","author":"Bucci","year":"2017","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.aohep.2021.100564_bib0028","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/liv.14735","article-title":"The changing scenario of hepatocellular carcinoma in Italy: an update","volume":"41","author":"Garuti","year":"2021","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.aohep.2021.100564_bib0029","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2009.01.001","article-title":"Hepatocellular carcinoma in patients with cryptogenic cirrhosis","volume":"7","author":"Giannini","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2021.100564_bib0030","doi-asserted-by":"crossref","unstructured":"Giannini EG, Marenco S, Bruzzone L, Savarino V, Farinati F, Del Poggio P, et\u00a0al. Hepatocellular carcinoma in patients without cirrhosis in Italy. Dig Liver Dis. 2013 Feb;45(2):164-9.","DOI":"10.1016\/j.dld.2012.08.018"},{"issue":"2","key":"10.1016\/j.aohep.2021.100564_bib0031","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1478-3231.2010.02409.x","article-title":"Relative decrease in the role played by hepatitis B virus infection in the aetiology of hepatocellular carcinoma during a 20-year period: a multicentre Italian study","volume":"31","author":"Giannini","year":"2011","journal-title":"Liver Int"},{"issue":"9","key":"10.1016\/j.aohep.2021.100564_bib0032","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/liv.12208","article-title":"Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres","volume":"33","author":"Cazzagon","year":"2013","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.aohep.2021.100564_bib0033","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/apt.13485","article-title":"Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome","volume":"43","author":"Bucci","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.aohep.2021.100564_bib0034","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1111\/liv.13877","article-title":"Metabolic disorders across hepatocellular carcinoma in Italy","volume":"38","author":"Morisco","year":"2018","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.aohep.2021.100564_bib0035","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/gut.2009.194217","article-title":"Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience","volume":"59","author":"Mirici-Cappa","year":"2010","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.aohep.2021.100564_bib0036","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/hep.510310211","article-title":"Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience","volume":"31","author":"Yuen","year":"2000","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.aohep.2021.100564_bib0037","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1053\/lv.2000.4875","article-title":"Improved survival with screening for hepatocellular carcinoma","volume":"6","author":"Wong","year":"2000","journal-title":"Liver Transpl"},{"issue":"8","key":"10.1016\/j.aohep.2021.100564_bib0038","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/j.1572-0241.2004.30137.x","article-title":"Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival","volume":"99","author":"Trevisani","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.aohep.2021.100564_bib0039","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1111\/j.1572-0241.2007.01395.x","article-title":"Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate\/advanced cirrhosis?","volume":"102","author":"Trevisani","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.aohep.2021.100564_bib0040","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jhep.2010.03.010","article-title":"Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival","volume":"53","author":"Santi","year":"2010","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2021.100564_bib0041","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/ajg.2012.449","article-title":"Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?","volume":"108","author":"Singal","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.aohep.2021.100564_bib0042","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/ajg.2013.98","article-title":"Surveillance for hepatocellular carcinoma: just do it!","volume":"108","author":"Giannini","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.aohep.2021.100564_bib0043","doi-asserted-by":"crossref","first-page":"261","DOI":"10.7326\/M14-0558","article-title":"Screening for hepatocellular carcinoma in chronic liver disease: a systematic review","volume":"161","author":"Kansagara","year":"2014","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.aohep.2021.100564_bib0044","doi-asserted-by":"crossref","first-page":"239","DOI":"10.7326\/L15-5049-2","article-title":"Screening for hepatocellular carcinoma in chronic liver disease","volume":"162","author":"Giannini","year":"2015","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.aohep.2021.100564_bib0045","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/hep.24196","article-title":"Alpha-fetoprotein in hepatocellular carcinoma surveillance: wake not the dead","volume":"54","author":"Giannini","year":"2011","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.aohep.2021.100564_bib0046","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3390\/cancers13040897","article-title":"Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients","volume":"13","author":"Pelizzaro","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.aohep.2021.100564_bib0047","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1586\/egh.12.30","article-title":"Effectiveness of alpha-fetoprotein for hepatocellular carcinoma surveillance: the return of the living-dead?","volume":"6","author":"Giannini","year":"2012","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.aohep.2021.100564_bib0048","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.cgh.2014.07.006","article-title":"Accuracy of alpha-fetoprotein measurement in detection of hepatocellular carcinoma\u20131 more nail in the coffin","volume":"12","author":"Giannini","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2021.100564_bib0049","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1572-0241.2006.00443.x","article-title":"Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?","volume":"101","author":"Farinati","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"14","key":"10.1016\/j.aohep.2021.100564_bib0050","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/cncr.28706","article-title":"Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use","volume":"120","author":"Giannini","year":"2014","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.aohep.2021.100564_bib0051","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/bjc.2014.536","article-title":"A new approach to the use of \u03b1-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis","volume":"112","author":"Biselli","year":"2015","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.aohep.2021.100564_bib0052","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.cgh.2014.02.025","article-title":"Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis","volume":"12","author":"Del Poggio","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.aohep.2021.100564_bib0053","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3390\/cancers12061422","article-title":"Surveillance for hepatocellular carcinoma in patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?","volume":"12","author":"Plaz Torres","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.aohep.2021.100564_bib0054","doi-asserted-by":"crossref","unstructured":"Trevisani F, Santi V. Prognostication of the outcome of hepatocellular carcinoma: how to rely on science instead of on the art of Nostradamus. Dig Liver Dis. 2009 Jun;41(6):382-4.","DOI":"10.1016\/j.dld.2009.03.001"},{"issue":"11","key":"10.1016\/j.aohep.2021.100564_bib0055","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.cgh.2006.08.011","article-title":"Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma","volume":"4","author":"Giannini","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2021.100564_bib0056","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1200\/JCO.18.00885","article-title":"Influence of HIV infection on the natural history of hepatocellular carcinoma: Results from a global multicohort study","volume":"37","author":"Pinato","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.aohep.2021.100564_bib0057","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1097\/MEG.0b013e32831a86f8","article-title":"Is female sex a significant favorable prognostic factor in hepatocellular carcinoma?","volume":"21","author":"Farinati","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2021.100564_bib0058","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/apt.16220","article-title":"Italian Liver Cancer (ITA.LI.CA) study group. Letter: is female sex really associated with better prognosis in hepatocellular carcinoma?","volume":"53","author":"Pelizzaro","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.aohep.2021.100564_bib0059","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1572-0241.2006.00364.x","article-title":"Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma","volume":"101","author":"Cantarini","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.aohep.2021.100564_bib0060","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/j.1572-0241.2007.01100.x","article-title":"Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance","volume":"102","author":"Trevisani","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.aohep.2021.100564_bib0061","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/hep.25814","article-title":"Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis","volume":"56","author":"Giannini","year":"2012","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.aohep.2021.100564_bib0062","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jhep.2017.01.033","article-title":"Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma","volume":"67","author":"Cabibbo","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2021.100564_bib0063","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/apt.13821","article-title":"Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon","volume":"45","author":"Petta","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.aohep.2021.100564_bib0064","doi-asserted-by":"crossref","unstructured":"Guarino M, Vigan\u00f2 L, Ponziani FR, Giannini EG, Lai Q, Morisco F, et\u00a0al. Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. Dig Liver Dis. 2018 Nov;50(11):1105-1114.","DOI":"10.1016\/j.dld.2018.08.001"},{"issue":"3","key":"10.1016\/j.aohep.2021.100564_bib0065","doi-asserted-by":"crossref","first-page":"e13056","DOI":"10.1111\/eci.13056","article-title":"Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals","volume":"49","author":"Giannini","year":"2019","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"10.1016\/j.aohep.2021.100564_bib0066","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2019.03.027","article-title":"Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients","volume":"71","author":"Cabibbo","year":"2019","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.aohep.2021.100564_bib0067","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/liv.13357","article-title":"A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma","volume":"37","author":"Cabibbo","year":"2017","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.aohep.2021.100564_bib0068","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/liv.14718","article-title":"Monofocal hepatocellular carcinoma: How much does size matter?","volume":"41","author":"Pelizzaro","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2021.100564_bib0069","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2407-9-33","article-title":"Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study","volume":"9","author":"Farinati","year":"2009","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.aohep.2021.100564_bib0070","doi-asserted-by":"crossref","first-page":"e13542","DOI":"10.1111\/eci.13542","article-title":"Pattern of macrovascular invasion in hepatocellular carcinoma","volume":"51","author":"Guarino","year":"2021","journal-title":"Eur J Clin Invest"},{"issue":"10","key":"10.1016\/j.aohep.2021.100564_bib0071","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/liv.12199","article-title":"Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients","volume":"33","author":"Giannini","year":"2013","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.aohep.2021.100564_bib0072","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1148\/radiol.2241011262","article-title":"Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials","volume":"224","author":"Camm\u00e0","year":"2002","journal-title":"Radiology"},{"issue":"9319","key":"10.1016\/j.aohep.2021.100564_bib0073","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.aohep.2021.100564_bib0074","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2036.2009.04198.x","article-title":"Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma","volume":"31","author":"Giannini","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.aohep.2021.100564_bib0075","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/j.1478-3231.2010.02220.x","article-title":"Transarterial chemoembolization in Child-Pugh class B patients with hepatocellular carcinoma: between the devil and the deep blue sea","volume":"30","author":"Giannini","year":"2010","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.aohep.2021.100564_bib0076","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1478-3231.2009.02128.x","article-title":"Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization","volume":"30","author":"Hsu","year":"2010","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2021.100564_bib0077","doi-asserted-by":"crossref","unstructured":"Campani C, Vitale A, Dragoni G, Arena U, Laffi G, Cillo U, et\u00a0al. Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Liver Cancer. 2021 Apr;10(2):126-136.","DOI":"10.1159\/000513404"},{"key":"10.1016\/j.aohep.2021.100564_bib0078","first-page":"1","article-title":"Recalibrating survival prediction among patients receiving trans-arterial chemoembolization for hepatocellular carcinoma","volume":"00","author":"Cucchetti","year":"2021","journal-title":"Liver Cancer Int"},{"issue":"4","key":"10.1016\/j.aohep.2021.100564_bib0079","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/ajg.2011.425","article-title":"Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors","volume":"107","author":"Shiina","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.aohep.2021.100564_bib0080","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1038\/ajg.2012.250","article-title":"Ten-year outcome of radiofrequency thermal ablation for hepatocellular carcinoma: an Italian experience","volume":"107","author":"Giannini","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.aohep.2021.100564_bib0081","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MEG.0b013e32834e153c","article-title":"Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicentre experience in Italy","volume":"24","author":"Farinati","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2021.100564_bib0082","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.5301\/jbm.5000117","article-title":"Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database","volume":"30","author":"Sacco","year":"2015","journal-title":"Int J Biol Markers"},{"issue":"8","key":"10.1016\/j.aohep.2021.100564_bib0083","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.dld.2020.12.001","article-title":"Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: a multicenter study","volume":"53","author":"Marasco","year":"2021","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.aohep.2021.100564_bib0084","doi-asserted-by":"crossref","DOI":"10.1016\/j.dld.2021.04.025","article-title":"Selecting an optimal prognostic model for advanced hepatocellular carcinoma: Any new ideas?","author":"Huo","year":"2021","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.aohep.2021.100564_bib0085","article-title":"Time to move beyond the classical prognostic systems for patients with advanced hepatocellular carcinoma undergoing Sorafenib","author":"Marasco","year":"2021","journal-title":"Dig Liver Dis"},{"issue":"11","key":"10.1016\/j.aohep.2021.100564_bib0086","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.3390\/cancers13112677","article-title":"A Nomogram-based prognostic model for advanced hepatocellular carcinoma patients treated with sorafenib: a multicenter study","volume":"13","author":"Marasco","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.aohep.2021.100564_bib0087","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1634\/theoncologist.2013-0093","article-title":"Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study","volume":"18","author":"Brandi","year":"2013","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.aohep.2021.100564_bib0088","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/liv.13242","article-title":"Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma","volume":"37","author":"Pecorelli","year":"2017","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.aohep.2021.100564_bib0089","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/liv.12649","article-title":"BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group","volume":"35","author":"Farinati","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2021.100564_bib0090","doi-asserted-by":"crossref","unstructured":"Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, et\u00a0al. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012 Nov;32(4):348-59.","DOI":"10.1055\/s-0032-1329906"},{"issue":"1","key":"10.1016\/j.aohep.2021.100564_bib0091","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/ajg.2015.389","article-title":"Application of the Intermediate-stage subclassification to patients with untreated hepatocellular carcinoma","volume":"111","author":"Giannini","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.aohep.2021.100564_bib0092","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/hep.29668","article-title":"Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice","volume":"67","author":"Giannini","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.aohep.2021.100564_bib0093","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/hep.29714","article-title":"Breaking Kuhn's paradigm in advanced hepatocellular carcinoma","volume":"67","author":"Pinato","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.aohep.2021.100564_bib0094","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002006","article-title":"Development and validation of a new prognostic system for patients with hepatocellular carcinoma","volume":"13","author":"Farinati","year":"2016","journal-title":"PLoS Med"},{"issue":"6","key":"10.1016\/j.aohep.2021.100564_bib0095","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1002\/hep.29662","article-title":"External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort study","volume":"67","author":"Borzio","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.aohep.2021.100564_bib0096","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/hep.31187","article-title":"Treatment of hepatocellular carcinoma in the Precision Medicine era: From Treatment Stage Migration to Therapeutic Hierarchy","volume":"72","author":"Vitale","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.aohep.2021.100564_bib0097","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1007\/s11605-021-04963-w","article-title":"Liver Resection for Patients with Intermediate Stage Hepatocellular Carcinoma: Beyond Rigid Staging Systems Towards a More Personalized Therapeutic Approach","volume":"25","author":"Giannini","year":"2021","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"10.1016\/j.aohep.2021.100564_bib0098","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/hep.27443","article-title":"Prognosis of untreated hepatocellular carcinoma","volume":"61","author":"Giannini","year":"2015","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.aohep.2021.100564_bib0099","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.3390\/cancers11111689","article-title":"Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice","volume":"11","author":"Giannini","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10.1016\/j.aohep.2021.100564_bib0100","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.3390\/jcm10153201","article-title":"Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab\/Bevacizumab in a Real-Life Setting","volume":"10","author":"Plaz Torres","year":"2021","journal-title":"J Clin Med"},{"issue":"10088","key":"10.1016\/j.aohep.2021.100564_bib0101","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.aohep.2021.100564_bib0102","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.aohep.2021.100564_bib0103","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268121002635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268121002635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:43:17Z","timestamp":1761648197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268121002635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":103,"alternative-id":["S1665268121002635"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2021.100564","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The ITA.LI.CA Consortium: How multicentre collaboration helped shape the management of patients with hepatocellular carcinoma on the basis of real-world evidence","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2021.100564","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C.","name":"copyright","label":"Copyright"}],"article-number":"100564"}}